Company
Breye Therapeutics
- Biotech
- Location:
- Horsholm, Denmark
Description
Breye Therapeutics develops orally administered ophthalmology drugs, including danegaptide and P2X7 receptor antagonists, to treat retinal vascular diseases such as diabetic retinopathy and age-related macular degeneration.
Breye Therapeutics is located in the Copenhagen ecosystem.
Related
ATXA TherapeuticsATXA Therapeutics develops selective small-molecule thromboxane receptor (TP) antagonists, including lead candidate NTP42, to treat…
- AplagonAplagon develops a therapeutic called APAC, a vascular-injury targeting molecule that combines antiplatelet, anticoagulant, and…
Confo TherapeuticsConfo Therapeutics develops GPCR-directed small-molecule and antibody therapies with proprietary technology that targets class A and B…
BraineverBrainever develops hEN1 and hOTX2 homeoprotein drug candidates intended to limit neurodegenerative disease progression by preventing…
Age LabsAge Labs develops biomarkers and predictive algorithms for early detection of age-related diseases, offering diagnostic tests, biological…
Bluedrop MedicalBluedrop Medical builds an at-home foot-health scanning system (OneStep Foot Scanner) and monitoring service to detect early diabetic foot…
KvantifyKvantify develops software and services that route calculations across quantum and classical architectures, accelerating molecular…
BIMINI BiotechBIMINI Biotech develops first-in-class small-molecule therapeutics targeting the Wiskott–Aldrich Syndrome protein for oncology and…
LEO PharmaLEO Pharma develops and delivers innovative treatments for medical dermatology, producing medicines and supplying healthcare providers and…